Efficacy and Safety of Mizoribine Combined With Tacrolimus in Living Donor Kidney Transplant Recipients: 3-Year Results by a Chinese Single Center Study |
| |
| Affiliation: | 1. Department of Urology, Beijing Tsinghua Changgung Hospital, Beijing, China;2. Organ Transplantation Center, Tianjin First Center Hospital, Tianjin, China;3. Institute of Liver Transplantation, General Hospital of Chinese People''s Armed Police Force, Beijing, China;1. Department of Medicine, John H. Stroger Hospital of Cook County, Chicago, Illinois, USA;2. Department of Cardiothoracic Surgery, RWJ Barnabas Health, Newark Beth Israel Medical Center, Newark, New Jersey;3. Department of Medicine, Meharry Medical College, Nashville, Tennessee, USA;4. Department of Internal Medicine, Brown University Memorial Hospital of Rhode Island, Providence, Rhode Island;5. Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana;6. Boston Consulting Group, Chicago, Illinois, USA;1. Department of Organ Transplantation and General Surgery, Kyoto Prefectural University of Medicine, Kajii-cho 465, Kamigyo-ku, Kyoto-prefecture, Japan;2. Wakunaga Pharmaceutical Co, Ltd, Molecular Diagnostics Division, Osaka, Japan;1. Department of Surgery, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung 210-711, Republic of Korea;2. Department of Hematology and Oncology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung 210-711, Republic of Korea;3. College of Korean Medicine, Gachon University, Seongnam 461-701, Republic of Korea;4. Department of Chemistry, Gangneung Wonju National University, Gangneung 210-340, Republic of Korea;5. Natural Product Research Center, Korea Institute of Science and Technology, Gangneung 210-340, Republic of Korea;6. Natural Product Research Laboratory, School of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea;7. Department of Oral Anatomy, College of Dentistry, Gangneung Wonju National University, 201-340, Republic of Korea;8. Department of Biological Chemistry, University of Science and Technology (UST), Daejeon 305-333, Republic of Korea;1. Department of Urology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan;2. Department of Pathology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan |
| |
| Abstract: | ![]()
BackgroundMizoribine (MZR) was effective and safe for living Chinese donor kidney transplantation (LDKT) on tacrolimus-based treatment 1 year after transplantation. We investigated whether MZR was effective and safe for LDKT on tacrolimus-based treatment with long follow-up periods.MethodsWe compared 22 LDKT recipients who were administered MZR, tacrolimus, and corticosteroids with a control group (n = 20) treated with mycophenolate mofetil (MMF), tacrolimus, and corticosteroids. Primary efficacy endpoints were 3-year patient survival, 3-year graft survival, and acute rejection (AR) rate within 3 years after transplantation.ResultsThe 3-year patient and graft survival rates for the MZR and MMF groups were 100%. The AR rate after transplantation was 18.2% for the MZR group and 10.0% for the MMF group; the difference was not significant (P = .665). There was no significant difference in serum creatinine levels, glomerular filtration rates (eGFR), serum urate levels, blood urea nitrogen, and cystatin C levels 12, 24, and 36 months after transplantation. No significant differences in the CD3, CD4, CD8, CD4/CD8, and CD45 were observed between the 2 groups 12, 24, and 36 months after transplantation. There were no significant differences in adverse events among the MZR or the MMF group, whereas the prevalence of gastrointestinal symptoms were significantly lower in the MZR treatment group (P = .003), especially acid reflux (P = .007). Compared with the MMF group, the MZR group should lighten the burden on patients.ConclusionMZR with tacrolimus and corticosteroids provides satisfactory immunosuppression and higher safety for Chinese LDKT over a 3-year follow-up. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
